JP2007530601A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007530601A5 JP2007530601A5 JP2007505341A JP2007505341A JP2007530601A5 JP 2007530601 A5 JP2007530601 A5 JP 2007530601A5 JP 2007505341 A JP2007505341 A JP 2007505341A JP 2007505341 A JP2007505341 A JP 2007505341A JP 2007530601 A5 JP2007530601 A5 JP 2007530601A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- formula
- optionally substituted
- alkyl
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 52
- 125000000217 alkyl group Chemical group 0.000 claims 18
- 238000000034 method Methods 0.000 claims 18
- 125000003118 aryl group Chemical group 0.000 claims 14
- 239000003814 drug Substances 0.000 claims 10
- 125000000623 heterocyclic group Chemical group 0.000 claims 9
- 229940079593 drug Drugs 0.000 claims 8
- 229920006395 saturated elastomer Polymers 0.000 claims 8
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 5
- 230000004770 neurodegeneration Effects 0.000 claims 5
- 208000015122 neurodegenerative disease Diseases 0.000 claims 5
- 230000000926 neurological effect Effects 0.000 claims 5
- 125000001072 heteroaryl group Chemical group 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- 230000002265 prevention Effects 0.000 claims 4
- 125000003342 alkenyl group Chemical group 0.000 claims 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 125000005843 halogen group Chemical group 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 102000012440 Acetylcholinesterase Human genes 0.000 claims 2
- 108010022752 Acetylcholinesterase Proteins 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- 229940022698 acetylcholinesterase Drugs 0.000 claims 2
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims 2
- 239000003963 antioxidant agent Substances 0.000 claims 2
- 230000003078 antioxidant effect Effects 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 208000025688 early-onset autosomal dominant Alzheimer disease Diseases 0.000 claims 2
- 230000001076 estrogenic effect Effects 0.000 claims 2
- 208000015756 familial Alzheimer disease Diseases 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 238000006396 nitration reaction Methods 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims 1
- 208000018282 ACys amyloidosis Diseases 0.000 claims 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 1
- 208000002177 Cataract Diseases 0.000 claims 1
- 208000005145 Cerebral amyloid angiopathy Diseases 0.000 claims 1
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 claims 1
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 claims 1
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 206010067889 Dementia with Lewy bodies Diseases 0.000 claims 1
- 201000010374 Down Syndrome Diseases 0.000 claims 1
- 208000007487 Familial Cerebral Amyloid Angiopathy Diseases 0.000 claims 1
- 208000032849 Hereditary cerebral hemorrhage with amyloidosis Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 208000009829 Lewy Body Disease Diseases 0.000 claims 1
- 208000026072 Motor neurone disease Diseases 0.000 claims 1
- 208000001089 Multiple system atrophy Diseases 0.000 claims 1
- 208000024777 Prion disease Diseases 0.000 claims 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims 1
- 208000034799 Tauopathies Diseases 0.000 claims 1
- 206010044688 Trisomy 21 Diseases 0.000 claims 1
- 206010002022 amyloidosis Diseases 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 230000001896 anti-amyloidogenic effect Effects 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 230000006999 cognitive decline Effects 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 238000006193 diazotization reaction Methods 0.000 claims 1
- -1 halo compound Chemical class 0.000 claims 1
- 150000004677 hydrates Chemical class 0.000 claims 1
- 206010022437 insomnia Diseases 0.000 claims 1
- 231100000518 lethal Toxicity 0.000 claims 1
- 230000001665 lethal effect Effects 0.000 claims 1
- 208000005264 motor neuron disease Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 230000000626 neurodegenerative effect Effects 0.000 claims 1
- 230000000324 neuroprotective effect Effects 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 238000007363 ring formation reaction Methods 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2004901802A AU2004901802A0 (en) | 2004-04-02 | Process for the preparation of intermediates | |
| AU2004901802 | 2004-04-02 | ||
| AU2004901804A AU2004901804A0 (en) | 2004-04-02 | Neurologically-active compounds | |
| AU2004901804 | 2004-04-02 | ||
| AU2004907359A AU2004907359A0 (en) | 2004-12-24 | Neurologically-active compounds | |
| AU2004907359 | 2004-12-24 | ||
| PCT/AU2005/000477 WO2005095360A1 (en) | 2004-04-02 | 2005-04-01 | Neurologically-active compounds |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007530601A JP2007530601A (ja) | 2007-11-01 |
| JP2007530601A5 true JP2007530601A5 (enExample) | 2009-06-25 |
| JP4937111B2 JP4937111B2 (ja) | 2012-05-23 |
Family
ID=35063693
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007505341A Expired - Fee Related JP4937111B2 (ja) | 2004-04-02 | 2005-04-01 | 神経学的に活性な化合物 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US8084459B2 (enExample) |
| EP (1) | EP1737831B1 (enExample) |
| JP (1) | JP4937111B2 (enExample) |
| BR (1) | BRPI0508183B8 (enExample) |
| CA (1) | CA2563038C (enExample) |
| DK (1) | DK1737831T3 (enExample) |
| ES (1) | ES2425476T3 (enExample) |
| IL (1) | IL178330A (enExample) |
| MX (1) | MXPA06011236A (enExample) |
| NZ (1) | NZ551004A (enExample) |
| WO (1) | WO2005095360A1 (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2440217T3 (es) * | 2002-10-04 | 2014-01-28 | Prana Biotechnology Limited | Compuestos neurológicamente activos |
| DK1737831T3 (da) | 2004-04-02 | 2013-08-19 | Prana Biotechnology Ltd | Neurologisk aktive forbindelser |
| EP2001875A2 (en) * | 2006-03-08 | 2008-12-17 | Takeda San Diego, Inc. | Glucokinase activators |
| BRPI0722382A2 (pt) * | 2006-04-14 | 2012-06-05 | Prana Biotechnology Ltd | compostos úteis para o tratamento de cáncer |
| JP4876690B2 (ja) * | 2006-04-21 | 2012-02-15 | 三菱瓦斯化学株式会社 | キナゾリン−４−オン誘導体の製造法 |
| JP5450407B2 (ja) | 2007-07-06 | 2014-03-26 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 置換アミノ−キナゾリノン、前記化合物を含む薬物、それらの使用及び製造方法 |
| AU2008305581C1 (en) * | 2007-09-26 | 2014-12-11 | Celgene Corporation | 6-, 7-, or 8-substituted quinazolinone derivatives and compositions comprising and methods of using the same |
| WO2010071944A1 (en) * | 2008-12-24 | 2010-07-01 | Prana Biotechnology Limited | Quinazolinone compounds |
| US8592485B2 (en) * | 2010-06-17 | 2013-11-26 | Healthpartners Research Foundation | Methods and pharmaceutical compositions for treating the animal central nervous system for psychiatric disorders |
| WO2012066330A1 (en) | 2010-11-17 | 2012-05-24 | Heptares Therapeutics Limited | Compounds useful as a2a receptor inhibitors |
| EP2565186A1 (en) * | 2011-09-02 | 2013-03-06 | Hybrigenics S.A. | Selective and reversible inhibitors of ubiquitin specific protease 7 |
| US10260089B2 (en) | 2012-10-29 | 2019-04-16 | The Research Foundation Of The State University Of New York | Compositions and methods for recognition of RNA using triple helical peptide nucleic acids |
| US8877766B2 (en) * | 2013-02-15 | 2014-11-04 | Peter F. Kador | Neuroprotective multifunctional antioxidants and their monofunctional analogs |
| TWI698436B (zh) | 2014-12-30 | 2020-07-11 | 美商佛瑪治療公司 | 作為泛素特異性蛋白酶７抑制劑之吡咯并及吡唑并嘧啶 |
| MA41291A (fr) | 2014-12-30 | 2017-11-07 | Forma Therapeutics Inc | Dérivés de la pyrrolotriazinone et de l'imidazotriazinone en tant qu'inhibiteurs de la protéase spécifique de l'ubiquitine n° 7 (usp7) pour le traitement d'un cancer |
| HK1248221A1 (zh) | 2015-02-05 | 2018-10-12 | Forma Therapeutics, Inc. | 异噻唑啉酮类，吡唑并嘧啶酮类和吡咯并嘧啶酮作为泛蛋白特异性蛋白酶7抑制剂 |
| EP3253738A1 (en) | 2015-02-05 | 2017-12-13 | Forma Therapeutics, Inc. | Quinazolinones and azaquinazolinones as ubiquitin-specific protease 7 inhibitors |
| EP3253765A1 (en) | 2015-02-05 | 2017-12-13 | Forma Therapeutics, Inc. | Thienopyrimidinones as ubiquitin-specific protease 7 inhibitors |
| US10781178B2 (en) | 2015-08-12 | 2020-09-22 | The General Hospital Corporation | 8-hydroxyquinoline derivatives as diagnostic and therapeutic agents |
| WO2019062803A1 (zh) | 2017-09-28 | 2019-04-04 | 基石药业 | 作为a2a受体抑制剂的并环类衍生物 |
| CN110330487B (zh) * | 2019-07-31 | 2023-03-24 | 西南大学 | 喹唑酮噻唑化合物及其制备方法和应用 |
| TW202208355A (zh) | 2020-05-04 | 2022-03-01 | 美商安進公司 | 作為骨髓細胞觸發受體2促效劑之雜環化合物及使用方法 |
| CN116322696A (zh) | 2020-05-04 | 2023-06-23 | 安进公司 | 作为髓样细胞上表达的触发受体2激动剂的杂环化合物和使用方法 |
| TW202309029A (zh) * | 2021-05-04 | 2023-03-01 | 美商維佳神經科學有限公司 | 作為骨髓細胞觸發受體2促效劑之雜環化合物及使用方法 |
| EP4430029A4 (en) * | 2021-11-09 | 2025-09-10 | Vigil Neuroscience Inc | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELL AGONISTS 2 AND METHODS OF USE |
| TW202325290A (zh) * | 2021-11-09 | 2023-07-01 | 美商維佳神經科學有限公司 | 作為骨髓細胞上表現之觸發受體２促效劑之雜環化合物及其使用方法 |
| WO2025059726A1 (en) * | 2023-09-22 | 2025-03-27 | Alterity Therapeutics Limited | Novel therapy |
| WO2026011223A1 (en) * | 2024-07-12 | 2026-01-15 | Alterity Therapeutics Limited | Novel salt and crystalline form |
| WO2026020054A1 (en) * | 2024-07-18 | 2026-01-22 | Neumora Therapeutics, Inc. | Compounds and methods for treating neurological disorders |
| US12703688B1 (en) | 2025-03-14 | 2026-08-11 | Alterity Therapeutics Limited | Crystalline form, and process for its production |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE505711A (enExample) | 1950-09-09 | |||
| US5756502A (en) | 1994-08-08 | 1998-05-26 | Warner-Lambert Company | Quinazolinone derivatives as cholyecystokinin (CCK) ligands |
| WO1997010221A1 (en) | 1995-09-15 | 1997-03-20 | Torrey Pines Institute For Molecular Studies | Synthesis of quinazolinone libraries |
| AU7179598A (en) | 1996-11-13 | 1998-06-03 | Cephalon, Inc. | Benzothiazo and related heterocyclic group-containing cysteine and serine protease inhibitors |
| BR9714222A (pt) | 1996-12-17 | 2000-04-18 | Du Pont | Método para o controle de doenças de plantas |
| US6337332B1 (en) * | 1998-09-17 | 2002-01-08 | Pfizer Inc. | Neuropeptide Y receptor antagonists |
| EP1514867A3 (en) * | 1998-10-22 | 2005-03-23 | NeuroSearch A/S | Substituted phenyl derivatives, their preparation and use |
| US6559160B1 (en) | 1999-08-27 | 2003-05-06 | Chemocentryx, Inc. | Compounds and methods for modulating cxcr3 function |
| EP1226129B1 (en) | 1999-10-27 | 2006-05-24 | Cytokinetics, Inc. | Methods and compositions utilizing quinazolinones |
| US6545004B1 (en) | 1999-10-27 | 2003-04-08 | Cytokinetics, Inc. | Methods and compositions utilizing quinazolinones |
| US6667300B2 (en) | 2000-04-25 | 2003-12-23 | Icos Corporation | Inhibitors of human phosphatidylinositol 3-kinase delta |
| DE60144277D1 (de) | 2000-04-25 | 2011-05-05 | Icos Corp | Hemmer der menschlichen phosphatidyl-inositol-3-kinase delta |
| AU2002227243A1 (en) | 2000-12-11 | 2002-06-24 | E.I. Du Pont De Nemours And Company | Quinazolinones and pyridinopyrimidinones for controlling invertebrate pests |
| CA2465491A1 (en) | 2001-11-07 | 2003-05-15 | Merck & Co., Inc. | Mitotic kinesin inhibitors |
| WO2003043961A2 (en) | 2001-11-19 | 2003-05-30 | Iconix Pharmaceuticals, Inc. | Modulators of rho c activity |
| AU2002346471A1 (en) | 2001-11-20 | 2003-06-10 | Cytokinetics, Inc. | Process for the racemization of chiral quinazolinones |
| US7009049B2 (en) | 2002-02-15 | 2006-03-07 | Cytokinetics, Inc. | Syntheses of quinazolinones |
| DE60336901D1 (de) * | 2002-03-07 | 2011-06-09 | X Ceptor Therapeutics Inc | Chinazolinon modulatoren von nukleinrezeptoren |
| WO2003084544A2 (en) | 2002-04-04 | 2003-10-16 | Cv Therapeutics, Inc. | Compounds dor increasing abca-1 expression useful for treating coronary artery disease and atherosclerosis |
| AU2002950217A0 (en) * | 2002-07-16 | 2002-09-12 | Prana Biotechnology Limited | 8- Hydroxy Quinoline Derivatives |
| EP1539180A4 (en) | 2002-08-21 | 2006-08-30 | Cytokinetics Inc | COMPOUNDS, COMPOSITIONS AND METHODS |
| ES2440217T3 (es) | 2002-10-04 | 2014-01-28 | Prana Biotechnology Limited | Compuestos neurológicamente activos |
| US9301829B2 (en) | 2003-07-30 | 2016-04-05 | Boston Scientific Scimed, Inc. | Embolic protection aspirator |
| US20050043239A1 (en) | 2003-08-14 | 2005-02-24 | Jason Douangpanya | Methods of inhibiting immune responses stimulated by an endogenous factor |
| US20050054614A1 (en) | 2003-08-14 | 2005-03-10 | Diacovo Thomas G. | Methods of inhibiting leukocyte accumulation |
| SI1689724T1 (sl) | 2003-11-25 | 2012-04-30 | Novartis Ag | Spojine kinazolinona kot sredstva proti raku |
| CA2552664A1 (en) | 2004-01-08 | 2005-07-28 | Michigan State University | Methods for treating and preventing hypertension and hypertension-related disorders |
| DK1737831T3 (da) | 2004-04-02 | 2013-08-19 | Prana Biotechnology Ltd | Neurologisk aktive forbindelser |
| EP1750714A1 (en) | 2004-05-13 | 2007-02-14 | Vanderbilt University | Phosphoinositide 3-kinase delta selective inhibitors for inhibiting angiogenesis |
| JPWO2005115993A1 (ja) | 2004-05-31 | 2008-03-27 | 萬有製薬株式会社 | キナゾリン誘導体 |
| JP2008501707A (ja) | 2004-06-04 | 2008-01-24 | アイコス、コーポレーション | マスト細胞障害を処置するための方法 |
| US20050282834A1 (en) | 2004-06-09 | 2005-12-22 | Fady Malik | Compositions, devices and methods for treating cardiovascular disease |
-
2005
- 2005-04-01 DK DK05714346.3T patent/DK1737831T3/da active
- 2005-04-01 NZ NZ551004A patent/NZ551004A/en not_active IP Right Cessation
- 2005-04-01 BR BRPI0508183A patent/BRPI0508183B8/pt not_active IP Right Cessation
- 2005-04-01 EP EP05714346.3A patent/EP1737831B1/en not_active Expired - Lifetime
- 2005-04-01 ES ES05714346T patent/ES2425476T3/es not_active Expired - Lifetime
- 2005-04-01 US US11/547,056 patent/US8084459B2/en not_active Expired - Lifetime
- 2005-04-01 CA CA2563038A patent/CA2563038C/en not_active Expired - Lifetime
- 2005-04-01 WO PCT/AU2005/000477 patent/WO2005095360A1/en not_active Ceased
- 2005-04-01 MX MXPA06011236A patent/MXPA06011236A/es active IP Right Grant
- 2005-04-01 JP JP2007505341A patent/JP4937111B2/ja not_active Expired - Fee Related
-
2006
- 2006-09-27 IL IL178330A patent/IL178330A/en active IP Right Grant
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2078578C (en) | Medical use for tachykinin antagonists | |
| DE60017898T2 (de) | Neuartige heterocyclische carboxamidderivate | |
| CA2500952A1 (en) | Neurologically-active compounds | |
| EP2813498B1 (en) | Compounds for Alzheimer's disease | |
| JPH07324076A (ja) | 新規なピラゾール−３−カルボキサミド誘導体、これらを製造するための方法及びこれらが存在する薬学的組成物 | |
| DE69529418T2 (de) | Cyclopropachromencarbonsäure derivate | |
| WO2002012189A1 (en) | Fused bicyclic amide compounds and medicinal use thereof | |
| JP6261011B2 (ja) | 眼疾患処置薬 | |
| BG65193B1 (bg) | Производно на пиразолкарбоксилна киселина, неговото използване и фармацевтични състави, които го съдържат | |
| RU2005100842A (ru) | Производные 8-гидроксихинолина | |
| JP4937111B2 (ja) | 神経学的に活性な化合物 | |
| JP2011507878A5 (enExample) | ||
| CN103781753B (zh) | 用于治疗ape1介导的疾病的醌化合物 | |
| JP2005531488A5 (enExample) | ||
| MXPA04002338A (es) | Derivados de carbazol y su uso como antagonistas receptores del npy5. | |
| JP2011507879A5 (enExample) | ||
| JP2007523909A5 (enExample) | ||
| JP2004507527A5 (enExample) | ||
| JPH02503909A (ja) | ６．１１‐ジヒドロ‐１１‐（４‐ピペリジリデン）‐５Ｈ‐ベンゾ［５，６］シクロヘプタ［１，２‐ｂ］ピリジン類ならびに組成物および使用法 | |
| JP6219955B2 (ja) | ベンゾフラザン抗アミロイド化合物および方法 | |
| KR20060132953A (ko) | 지양제 | |
| JP5341521B2 (ja) | タンパク質と結合パートナーとの相互作用を阻害するための化合物及び方法 | |
| RU2003101396A (ru) | Замещенные нитрированные катехолы, их применение в лечении некоторых расстройств центральной и периферической нервной системы и содержащие их фармацевтические композиции | |
| JPS6056957A (ja) | エチレンジアミン誘導体 | |
| CA2589744A1 (en) | Pyrrolinidium derivatives as m3 muscarinic receptors |